Applying New Stem Cell Science to Reboot the Immune System

Magenta Therapeutics is a biotechnology company developing therapeutics to revolutionize bone marrow transplant for patients with autoimmune diseases, blood cancers and genetic diseases. By creating a platform focused on critical areas of transplant medicine, Magenta Therapeutics is pioneering an integrated approach to extend the curative power of bone marrow transplant to more patients.

Year Invested: 2016
Location: Cambridge, Mass.

Recent News

March 8, 2018
Magenta Therapeutics Strengthens Leadership Team with Promotions, New Hires

March 5, 2018
Magenta Therapeutics and Heidelberg Pharma Sign Exclusive Multi-Target Research Agreement for the Development of Antibody Drug Conjugates

February 26, 2018
Magenta Therapeutics Presents Clinical and Preclinical Data at ASBMT Conference, Including New Preclinical Results on Microglial Engraftment with MGTA-456 Expanded Cord Blood Stem Cell Product

Read More News

Associated Team Members

Alexis Borisy